Florian Nachon

Bretigny, 91220, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and Butyrylcholinesterase for the Modulation of Neuroinflammation and Cognitive Dysfunction.

Journal: Journal of medicinal chemistry

Published: May 06, 2026

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: April 13, 2026

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: April 13, 2026

Combining β2-AR agonism with butyrylcholinesterase inhibition, a synergistic neuroprotective action against Alzheimer's disease.

Combining β2-AR agonism with butyrylcholinesterase inhibition, a synergistic neuroprotective action against Alzheimer's disease.

Journal: RSC medicinal chemistry

Published: March 30, 2026

Design, synthesis and evaluation of an uncharged broad spectrum quinoline-oxime hybrid for the reactivation of nerve agent-inhibited human acetylcholinesterase.

Design, synthesis and evaluation of an uncharged broad spectrum quinoline-oxime hybrid for the reactivation of nerve agent-inhibited human acetylcholinesterase.

Journal: European journal of medicinal chemistry

Published: March 24, 2026

Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer's disease model.

Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer's disease model.

Journal: European journal of medicinal chemistry

Published: January 15, 2026

Dual cholinergic modulation in dementia: Quinuclidine carbamates targeting butyrylcholinesterase and α7 nicotinic receptor.

Dual cholinergic modulation in dementia: Quinuclidine carbamates targeting butyrylcholinesterase and α7 nicotinic receptor.

Journal: Chemico-biological interactions

Published: September 18, 2025

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors.

Journal: Journal of medicinal chemistry

Published: August 08, 2025

N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors.

N-Propargylpyrrolidine-based butyrylcholinesterase and monoamine oxidase inhibitors.

Journal: Chemico-biological interactions

Published: June 30, 2025

Challenges and advances in the development of antidotes against A-series nerve agents.

Challenges and advances in the development of antidotes against A-series nerve agents.

Journal: Archives of toxicology

Published: June 24, 2025

Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease.

Lead Optimization of a Butyrylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease.

Journal: Journal of medicinal chemistry

Published: June 02, 2025

Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Chiral switch of a butyrylcholinesterase inhibitor for the treatment of Alzheimer's disease.

Journal: Chemico-biological interactions

Published: May 23, 2025

Showing 1-12 of 94

Last Updated: 09/26/2026